Trial
NCT02000453
Safety and Tolerability Study of GSK2586184 in Patients With Moderate to Severely Active Ulcerative Colitis.
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
GlaxoSmithKline
Collaborators
Prof Geert D'Haens, AMC, Amsterdam
Condition
Colitis, Ulcerative
Intervention
GSK2586184 400mg
Why stopped
GSK has elected to terminate development principally as a result of the statin drug-drug interaction (DDI) study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-10-09